# Atara Biotherapeutics (stock symbol: ATRA) Logo in transparent PNG and SVG formats

## Atara Biotherapeutics Logo large

### Atara Biotherapeutics Logo large Download PNG (26.46 KB)

![Atara Biotherapeutics Logo large Download PNG (26.46 KB)](/img/orig/ATRA_BIG-6aad6f0f.png)

### Atara Biotherapeutics Logo large Download SVG (6.98 KB)

![Atara Biotherapeutics Logo large Download SVG (6.98 KB)](/img/orig/ATRA_BIG-20e00120.svg)

## Atara Biotherapeutics Logo icon format

### Atara Biotherapeutics Logo icon format Download PNG (50.29 KB)

![Atara Biotherapeutics Logo icon format Download PNG (50.29 KB)](/img/orig/ATRA-e0c5e14f.png)

### Atara Biotherapeutics Logo icon format Download SVG (1.32 KB)

![Atara Biotherapeutics Logo icon format Download SVG (1.32 KB)](/img/orig/ATRA-22fadafa.svg)

## Atara Biotherapeutics Logo large for dark backgrounds

### Atara Biotherapeutics Logo large for dark backgrounds Download PNG (26.11 KB)

![Atara Biotherapeutics Logo large for dark backgrounds Download PNG (26.11 KB)](/img/orig/ATRA_BIG.D-ce7a77fd.png)

### Atara Biotherapeutics Logo large for dark backgrounds Download SVG (6.98 KB)

![Atara Biotherapeutics Logo large for dark backgrounds Download SVG (6.98 KB)](/img/orig/ATRA_BIG.D-b2131cf6.svg)

## About Atara Biotherapeutics

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

1. Website domain: atarabio.com
2. Employees: 578
3. Marketcap: $0.26 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
